Skip to main content
Article thumbnail
Location of Repository

Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours

By Alexandra Buhles, Sara A Collins, Jan P van Pijkeren, Simon Rajendran, Michelle Miles, Gerald C O'Sullivan, Deirdre M O'Hanlon and Mark Tangney

Abstract

The most common cause of death of cancer sufferers is through the occurrence of metastases. The metastatic behaviour of tumour cells is regulated by extracellular growth factors such as hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, and aberrant expression/activation of the c-Met receptor is closely associated with metastatic progression. Nk4 (also known as Interleukin (IL)32b) is a competitive antagonist of the HGF c-Met system and inhibits c-Met signalling and tumour metastasis. Nk4 has an additional anti-angiogenic activity independent of its HGF-antagonist function. Angiogenesis-inhibitory as well as cancer-specific apoptosis inducing effects make the Nk4 sequence an attractive candidate for gene therapy of cancer. This study investigates the inhibition of tumour metasasis by gene therapy mediated production of Nk4 by the primary tumour. Optimal delivery of anti-cancer genes is vital in order to achieve the highest therapeutic responses. Non-viral plasmid delivery methods have the advantage of safety and ease of production, providing immediate transgene expression, albeit short-lived in most tumours. Sustained presence of anti-angiogenic molecules is preferable with anti-angiogenic therapies, and the long-term expression mediated by Adeno-associated Virus (AAV) might represent a more appropriate delivery in this respect. However, the incubation time required by AAV vectors to reach appropriate gene expression levels hampers efficacy in many fast-growing murine tumour models. Here, we describe murine trials assessing the effects of Nk4 on the spontaneously metastatic Lewis Lung Carcinoma (LLC) model when delivered to primary tumour via plasmid lipofection or AAV2 vector. Intratumoural AAV-Nk4 administration produced the highest therapeutic response with significant reduction in both primary tumour growth and incidence of lung metastases. Plasmid-mediated therapy also significantly reduced metastatic growth, but with moderate reduction in primary subcutaneous tumour growth. Overall, this study demonstrates the potential for Nk4 gene therapy of metastatic tumours, when delivered by AAV or non-viral methods

Topics: Short Paper
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2669068
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol
    2. (1989). Drug treatments for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival. Cancer Res
    3. (1997). Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration.
    4. (1997). HGF/ NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett
    5. (2003). JC: In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates.
    6. (2000). Kringle 1–4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun
    7. (2007). Lewin AS: Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus. Genet Vaccines Ther
    8. (2003). Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. P r o c N a t l A c a d S c i U S A
    9. (1997). Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp
    10. (2008). MH: Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin Cancer Res
    11. (2000). RB: Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun
    12. (1999). T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol
    13. (2003). T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci
    14. (2006). Tabata Y: Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression.
    15. (2004). Tabata Y: Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther
    16. (2002). Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther
    17. (2008). Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther
    18. (2005). WR: Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.